BKIT – Blake Insomnia Therapeutics, Inc.
Blake Insomnia Therapeutics, Inc. is a New York-based pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia. Their patent-pending compound, Zleepax™ (ZLX-1), has demonstrated efficacy without causing side effects identified as the No. 1 problem with current sleep medication. Blake Insomnia completed its reverse merger into NASDAQ OTC in second half of 2015.
The Blake Insomnia management team consist of founder and CEO Birger Jan Olsen. The company is currently transitioning from a lean startup organization into a more mature organizational form. Plans for 2016 include establishing a board of directors, appointing a science advisory board and hiring additional required staff.
In 2007, we filed patent application EP20080758258, covering the use of specific beta blockers, alone or in combination with other anti-insomnia drugs, for the treatment of stress-related insomnia.
The first sleep aid using Beta Blockers
ZleepaxTM is the first sleep aid with beta blockers as the major active agent. First generation beta blockers inhibited natural melatonin secretion and had a negative impact on sleep3. Recent publications have shown that certain third-generation beta blockers actually improve quality of sleep for patients with mild hypertension.
These third-generation beta blockers has been widely used to treat hypertension since the early 1990s, is well tolerated in chronic use, has an attractive side-effect profile5, and should thus perform excellently applied as a sleep enhancer. Our patent application6 cover the use of beta blockers such as Nebivolol—alone or in combination with other anti-insomnia drugs—for the treatment of stress-related insomnia
Specifically, For stress-related insomnia
Stress is one of the most common causes of insomnia1. However, the relationship between insomnia and stress is complex—with the one often causing or exacerbating the other. A divorce or financial troubles, for example, can cause stress that leads to transient insomnia. This, in turn, can make the person less able to cope during the day, creating further stress. In a vicious circle, the further stress can eventually lead to intermittent or even chronic insomnia, where many patients name stress symptoms such as a pounding heart as what keep them awake at night2.
Where traditional hypnotics “force” people to sleep by depressing the central nervous system, ZleepaxTM (ZLX-1) acts by diminishing the physical symptoms of stress that keep people awake at night.
No more residual Daytime sedation
According to patients, the No. 1 problem with traditional sleeping pills is residual daytime sedation. The potential for tolerance build-up and addiction are also major perceived disadvantages7. Based on beta blockers, ZleepaxTM dramatically reduces these and many other unwanted side effects. This means that, in stark contrast to existing hypnotics, ZleepaxTM should be able to give many patients a better night’s sleep with fewer of the side effects they do not want.
Birger Jan Olsen, Inventor, Founder and CEO
The founder and CEO Birger Jan Olsen is a seasoned executive, inventor and marketer who has spent over 30 years working primarily in pharmaceuticals and medical devices. In addition to Blake Insomnia Therapeutics, Birger has founded some 10 business, including the pioneering neuromarketing company Mindmetic and ProjektGruppen, a successful pharma-focused marketing agency.
As an inventor, Birger developed Blake’s patent-pending ZLX-1 sleep medicine compound, along with a patented method for automatically interpreting brain activity, a compliance-boosting dosing device for osteoporosis patients, acquired by Roche Pharmaceuticals, and the widely used Globase automated marketing tool, acquired by AdPepper. Birger’s career-long focus on startups has given him a wealth of experience with early-stage business processes, including fundraising and early organizational development.
Financials & Filings
Visit: http://www.otcmarkets.com/stock/BKIT/company-info to see complete details.
Press Releases have not been investigated by SizzlingStockPicks, therefore we have no idea if the content of this news is based on Fact or Fiction. Although the link for the following press release may be from a familiar and reputable news source, you should NOT assume that a press wire hosted by a website you are familiar with is accurate just because it is on their site. SizzlingStockPicks will not be held responsible for any news release, including and not limited to misleading or non-factual content, or the accuracy of the identity of the given source of the press release.
GlobeNewswire•January 17, 2017
Blake Insomnia Therapeutics Inc. Seeks Financing for Clinical Trials
GuruFocus.com – January 4, 2017
Blake Insomnia CEO Dreams of Improving Sleep
Posted January 9, 2017
Blake Insomnia Therapeutics Inc (OTCMKTS:BKIT) Is Attempting To Succeed Where Merck & Co., Inc. (NYSE:MRK) and GlaxoSmithKline plc (ADR) (NYSE:GSK) Have Failed
244, 5th Avenue, Suite A-154,
N.Y. 10001, New York, USA
+1 888 612 2905
G6 Stocks LLC of which SizzlingStockPicks is a subsidiary, has been compensated 15,000 dollars to advertise BKIT by 3rd party media buyer BAS1 LLC who was compensated by Global Investment Advisors Inc.